Department of Neurology, University of Texas Health Science Center, Houston, TX 77030, USA.
Lancet Neurol. 2013 Mar;12(3):275-84. doi: 10.1016/S1474-4422(13)70013-9.
Ischaemic stroke is one of the leading causes of death and disability worldwide, and intravenous alteplase is the only proven effective treatment in the acute setting. Hypothermia has been shown to improve neurological outcomes after global ischaemia-hypoxia in comatose patients who have had cardiac arrest, and is one of the most extensively studied and powerful therapeutic strategies in acute ischaemic stroke. The protective mechanisms of therapeutic hypothermia affect the ischaemic cascade across several parallel pathways and, when coupled with reperfusion strategies, might yield synergistic benefits for patients who have had a stroke. Technological advances have allowed hypothermia to be induced rapidly, and the treatment has been used safely in acute stroke patients. Conclusive efficacy trials assessing therapeutic hypothermia combined with reperfusion therapies in acute ischaemic stroke are ongoing.
缺血性脑卒中是全球范围内导致死亡和残疾的主要原因之一,而静脉注射阿替普酶是急性治疗中唯一被证实有效的治疗方法。低温治疗已被证明可改善心搏骤停后昏迷患者的全球缺血缺氧性脑损伤的神经功能结局,并且是急性缺血性脑卒中研究最多、最有效的治疗策略之一。低温治疗的保护机制通过多个平行途径影响缺血级联反应,与再灌注策略相结合,可能为脑卒中患者带来协同效益。技术进步使得低温诱导变得迅速,并且该治疗方法已在急性脑卒中患者中安全使用。目前正在进行评估低温治疗联合再灌注治疗急性缺血性脑卒中的疗效的关键性试验。